FUMITAKA HAYASHI, PHD, MD
Psychiatric at Beechwood Ln, Kinnelon, NJ

License number
New Jersey 25MA09692700
Category
Psychiatric
Type
Psychiatry
Address
Address
14 Beechwood Ln, Kinnelon, NJ 07405
Phone
(973) 527-3372

Professional information

Fumitaka Hayashi Photo 1

Toll-Like Receptor 5 Ligands And Methods Of Use

US Patent:
2005014, Jul 7, 2005
Filed:
Nov 16, 2004
Appl. No.:
10/991347
Inventors:
Alan Aderem - Seattle WA, US
Fumitaka Hayashi - Kinnelon NJ, US
Kelly Smith - Seattle WA, US
David Underhill - Seattle WA, US
Adrian Ozinsky - Seattle WA, US
International Classification:
A61K039/02, C12N009/00, C07K014/195
US Classification:
424242100, 435183000, 530350000
Abstract:
The invention provides an immunomodulatory flagellin peptide having substantially the same amino acid sequence GALNEINNNLQRVRELAVQSANSTNSQSDLDSIQAEITQ (SEQ ID NO:44), or a modification thereof, and having toll like receptor 5 (TLR5) binding. The immunomodulatory flagellin peptide also can have substantially the same amino acid sequence TQFSGVKVLAQDNTLTIQVGANDGETIDIDLKQINS QTLGLDTL (SEQ ID NO:45); EGALNEINNNLQRVRELAVQSANSTNSQSDLDSIQAEITQRLNEIDRVNG (SEQ ID NO:46) or MAQVINTNSLSLLTQNNLNKSQSALGTAIERLSSGLRINSAKDDAAGQAIANF TANIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELAVQS (SEQ ID NO:47), or a modification thereof. Also provided is an immunomodulatory flagellin peptide having substantially the same amino acid sequence LQKIDAALAQVDTLRSDLGAVQNRFNSAITNL (SEQ ID NO:48), or a modification thereof, and having toll like receptor 5 (TLR5) binding. The immunomodulatory flagellin peptide also can have substantially the same amino acid sequence TLRSDLGAVQNRFNSAITNLGNTVNNLSS (SEQ ID NO:49) or EQAAKTTENPLQKIDAALAQVDTLRSDLGAVQNRFNSAITNLGNTVNNLSS (SEQ ID NO:50), or a modification thereof. Further provided is an immunomodulatory flagellin peptide having substantially the same amino acid sequence GALNEINNNLQRVRELAVQSANSTNSQSDLDSIQAE ITQ (SEQ ID NO:44) and substantially the same amino acid sequence LQKIDAALAQVDTLRSDLGAVQNRFNSAITNL (SEQ ID NO:48), or a modification thereof, and having toll like receptor 5 (TLR5) binding. Methods of using immunomodulatory flagellin peptides additionally are provided.